Analyse Hikma Pharmaceuticals plc

Fundamentele Analyse : H1 2017


Fundamentele Analyse : FY 2016


Fundamentele Analyse : FY 2015

Said Darwazah, Chairman and Chief Executive Officer of Hikma, said:

“Following an exceptional 2014, our Branded and Injectables businesses performed strongly in 2015 and we made excellent strategic progress in US Generics, transforming the future prospects of the Group.

Our businesses in MENA are performing very well. We achieved excellent growth in our key markets in 2015 whilst continuing to invest in our pipeline to support future growth. In Europe, we made significant investments in our injectable manufacturing capabilities, utilising equipment transferred from the Ben Venue site. In the US, Bedford is now well integrated and the pace of new injectables launches is accelerating.

The integration of the acquisition of Roxane, which closed at the end of February, will be a key focus this year and will transform our non-injectables business in the US, adding complementary and well differentiated products, an attractive pipeline, proven R&D capabilities and greater overall scale.

We have taken important strategic steps this year. Our focus in the short term will be on integrating Roxane and delivering high value, differentiated product launches. From 2017, we expect the benefits from the investments that we have made in recent years – in R&D, M&A, co-development partnerships and licensing agreements – to accelerate. Wehaveanexcitingpipelineacrossourbusinesssegmentsthatwilldriveacceleratedandsustainable future growth.”

 

Source : Hikma Pharmaceuticals plc Press Release, London (UK), March 16 2016